146 related articles for article (PubMed ID: 10219467)
1. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye.
Sjöquist B; Uhlin A; Byding P; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):234-9. PubMed ID: 10219467
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
Sjöquist B; Tajallaei S; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):225-33. PubMed ID: 10219466
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.
Sjöquist B; Johansson A; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):240-9. PubMed ID: 10219468
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit.
Sjöquist B; Basu S; Byding P; Bergh K; Stjernschantz J
Drug Metab Dispos; 1998 Aug; 26(8):745-54. PubMed ID: 9698288
[TBL] [Abstract][Full Text] [Related]
5. Ocular and systemic pharmacokinetics of latanoprost in humans.
Sjöquist B; Stjernschantz J
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S6-12. PubMed ID: 12204697
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
7. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
Wang RF; Gagliuso DJ; Mittag TW; Podos SM
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
Raber S; Courtney R; Maeda-Chubachi T; Simons BD; Freedman SF; Wirostko B;
Ophthalmology; 2011 Oct; 118(10):2022-7. PubMed ID: 21788077
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
[TBL] [Abstract][Full Text] [Related]
15. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
Stjernschantz J; Selén G; Astin M; Resul B
Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy.
Calissendorff B; Sjöquist B; Högberg G; Grunge-Lowerud A
J Ocul Pharmacol Ther; 2002 Apr; 18(2):127-31. PubMed ID: 12002666
[TBL] [Abstract][Full Text] [Related]
17. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans.
Ishii K; Tomidokoro A; Nagahara M; Tamaki Y; Kanno M; Fukaya Y; Araie M
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2957-63. PubMed ID: 11687542
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie M
J Glaucoma; 2012 Feb; 21(2):123-8. PubMed ID: 21423041
[TBL] [Abstract][Full Text] [Related]
19. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
20. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
